GSK, Johnson & Johnson, and Incyte Make Strategic Moves in Oncology and Rare Diseases

　　【Pharmaceutical Network | Industry Trends] Since 2026, M&A activities among multinational pharmaceutical companies have continued to heat up. In recent days alone, GSK China, Johnson & Johnson, and Incyte have successively announced acquisition deals. Overall, these transactions exhibit distinct characteristics: frequent large-scale deals, premiums for platform technologies, and a rush to acquire late-stage assets.
 

June 8 News: GlaxoSmithKline (GSK) is in discussions to acquire oncology drugmaker Nuvalent, Inc. (NUVL.US), with a transaction value between $9 billion and $10 billion.
 

It is reported that Nuvalent’s value lies in its pipeline of precision targeted therapies for non-small cell lung cancer (NSCLC). Through this acquisition, GSK will gain immediate access to multiple late-stage assets with multi-blockbuster potential. This will not only directly fill gaps in its oncology portfolio but also create synergies with its internally developed B7-H3-targeted antibody-drug conjugate (ADC), Ris-Rez, positioning the company to establish a robust product matrix in the lung cancer field.
 

It is worth noting that, in an effort to expand its existing product pipeline, GSK China agreed as early as January this year to acquire RAPT Therapeutics (RAPT.US), a U.S. biotechnology company focused on the research and development of therapies for inflammatory and immune diseases, for $2.2 billion. In another transaction, it also acquired a pulmonary arterial hypertension drug.
 

In related news, Johnson & Johnson plans to acquire biotechnology company Firefly Bio for $1 billion in cash, aiming to expand its oncology drug development pipeline. Firefly’s proprietary Firelink platform offers unique technological advantages, utilizing antibodies to precisely deliver a protein-degrading drug directly to cancer cells.
 

Johnson & Johnson stated that Firefly’s technological approach offers superior protection of healthy tissues and reduces damage to normal tissues when targeting tumors, compared with existing therapies. Consequently, this acquisition is expected to bring new breakthroughs and development opportunities to Johnson & Johnson’s anticancer drug R&D efforts, while further expanding its footprint in the cancer treatment market.
 

Furthermore, pharmaceutical company Incyte has recently announced plans to acquire the privately held STAR Therapeutics for up to $2 billion. Incyte focuses its business on hematology/oncology and inflammatory and autoimmune diseases, with marketed products including JAKAFI (ruxolitinib), MONJUVI (tafasitamab), and PEMAZYRE (pemigatinib).
 

Through this acquisition, Incyte will obtain the rights to STAR Therapeutics' core investigational drug, VGA039. This drug is a monoclonal antibody targeting Protein S, with dual mechanisms of action that promote platelet adhesion and enhance fibrin deposition to restore hemostasis. Currently, Phase 3 clinical trials for this drug have been initiated in patients with all types of von Willebrand disease (VWD).
 

Industry analysts believe that the leading acquisition models of multinational pharmaceutical companies have shifted from "scale expansion" to "precise strengthening," while platform-based technology acquisitions are gradually becoming mainstream. This indicates that future industry competition will no longer be about the success or failure of "which product," but rather who can effectively transform acquired assets into growth drivers.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.